New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
05:26 EDTAMPEAmpio announces active IND for Optina for treatment of DME
Ampio Pharmaceuticals announced that the FDA has accepted the company's IND for Optina for the treatment of Diabetic Macular Edema, or DME. Ampio plans to commence enrollment in a clinical trial in Q1. The FDA granted Optina 505 b 2 status in July, 2012. Drugs designated under this pathway can be approved on a single trial.
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
07:42 EDTAMPEAmpio confirms sales agreement with Cantor Fitzgerald
Ampio Pharmaceuticals entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald. CEO Michael Macaluso stated "During our most recent conference call, we stated that we are not currently raising money and that we have enough money to get us through 2016 and into 2017 and still complete all of our current objectives and nothing has changed since that conference call. The "at-the-market" program may be used opportunistically and as a contingency facility to strengthen our position post-Ampion trial data."
07:36 EDTAMPEAmpio enters $20M controlled equity offering sales agreement with Cantor
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use